Paper40323342
Differentiating IL-23 Inhibitors in Crohn's Disease.
Nardone OM and 4 others. Drugs, 2025. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Differentiating IL-23 Inhibitors in Crohn's Disease. Papers, record 40323342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40323342
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Crohn Disease | Major topic |
| Interleukin-23 | Major topic |
| Humans |
Source PubMed
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29909019 | Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. | Gastroenterology | 2018 | https://conductscience.org/library/papers/29909019 | PubMed |
| 2 | 35839335 | Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. | J Dermatolog Treat | 2022 | https://conductscience.org/library/papers/35839335 | PubMed |
| 3 | 30032288 | Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study. | J Crohns Colitis | 2018 | https://conductscience.org/library/papers/30032288 | PubMed |
| 4 | 38104569 | Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. | Lancet Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/38104569 | PubMed |
| 5 | 27189910 | Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. | Clin Gastroenterol Hepatol | 2016 | https://conductscience.org/library/papers/27189910 | PubMed |
| 6 | 35644155 | Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. | Lancet | 2022 | https://conductscience.org/library/papers/35644155 | PubMed |
| 7 | 39461795 | IL-23 inhibition for chronic inflammatory disease. | Lancet | 2024 | https://conductscience.org/library/papers/39461795 | PubMed |
| 8 | 39018531 | Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. | N Engl J Med | 2024 | https://conductscience.org/library/papers/39018531 | PubMed |
| 9 | 2504877 | Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. | J Exp Med | 1989 | https://conductscience.org/library/papers/2504877 | PubMed |
| 10 | 38215029 | Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study. | Inflamm Bowel Dis | 2024 | https://conductscience.org/library/papers/38215029 | PubMed |
| 11 | 35644154 | Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. | Lancet | 2022 | https://conductscience.org/library/papers/35644154 | PubMed |
| 12 | 16267322 | Natalizumab induction and maintenance therapy for Crohn's disease. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16267322 | PubMed |
| 13 | 34652810 | Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. | Br J Dermatol | 2022 | https://conductscience.org/library/papers/34652810 | PubMed |
| 14 | 33127595 | Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. | Clin Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/33127595 | PubMed |
| 15 | 31280967 | Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. | Lancet | 2019 | https://conductscience.org/library/papers/31280967 | PubMed |
| 16 | 27959607 | Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27959607 | PubMed |
| 17 | 35691323 | Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. | Lancet | 2022 | https://conductscience.org/library/papers/35691323 | PubMed |
| 18 | 38437854 | Crohn's disease. | Lancet | 2024 | https://conductscience.org/library/papers/38437854 | PubMed |
| 19 | 40113101 | Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study. | Gastroenterology | 2025 | https://conductscience.org/library/papers/40113101 | PubMed |
| 20 | 30824404 | Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. | Lancet Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/30824404 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42433375 | Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease. | Front Immunol | 2026 | https://conductscience.org/library/papers/42433375 | PubMed |
| 42012779 | Interleukin-23 Inhibitors in Inflammatory Bowel Disease. | BioDrugs | 2026 | https://conductscience.org/library/papers/42012779 | PubMed |
| 41745409 | Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions. | J Pers Med | 2026 | https://conductscience.org/library/papers/41745409 | PubMed |
| 41460707 | Modification of the dextran sodium sulfate model to identify agents that induce or exacerbate inflammatory bowel disease. | J Immunotoxicol | 2026 | https://conductscience.org/library/papers/41460707 | PubMed |
| 41339249 | Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. | Ann Med | 2025 | https://conductscience.org/library/papers/41339249 | PubMed |
| 41226868 | Personalizing IL-23 Inhibitor Therapy in IBD: Current Evidence and Future Directions in Therapeutic Drug Monitoring and Dose Optimization. | J Clin Med | 2025 | https://conductscience.org/library/papers/41226868 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IL12B | 3593 | PubTator's text mining | https://conductscience.org/library/genes/3593 | NCBI Gene |
| IL23A | 51561 | PubTator's text mining | https://conductscience.org/library/genes/51561 | NCBI Gene |
| IL37 | 27178 | PubTator's text mining | https://conductscience.org/library/genes/27178 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40323342
GET https://conductscience.org/api/papers/v1/40323342/references?page=2